Department of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Nanoscale Horiz. 2020 Jan 1;5(1):25-42. doi: 10.1039/c9nh00291j. Epub 2019 Jun 28.
Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
心血管疾病（CVD）包括多种可影响心脏和血管的疾病，是现代医疗保健面临的重大挑战。近三分之一的人患有某种形式的 CVD，许多人患有多种或相互交织的疾病，最终可能导致创伤性事件，如心脏病发作或中风。尽管过去一个世纪在心血管系统方面的知识为开发延长生命的药物和治疗方法铺平了道路，但 CVD 仍然是发达国家的主要死亡原因之一。最近，研究人员探索了纳米技术的应用，以改进 CVD 管理的当前临床范例。纳米级递药系统具有许多优点，包括靶向病变部位、提高药物生物利用度和携带各种功能有效载荷的能力。在这篇综述中，我们介绍了纳米颗粒技术在 CVD 诊断和治疗中的不同应用方式。详细讨论了具有增强功能的新型仿生平台的开发。
